CNI MONITOR. Developed by doctors for doctors. The new tool for drug efficacy. VISIT US on Chronix Booth #5147 Chronix Biomedical has published recently its results of a blinded prospective clinical trial validating the [...]
Tumor-specific cell free DNA (cfDNA) present in serum and plasma provides a real-time, easily accessible surrogate. We demonstrated variations in the number of cfDNA sequences circulating in the serum of patients with prostate cancer compared with healthy controls.
Genome profiling of individual tumors is provided by high-throughput sequencing and is about to enter routine clinical practice with impact on treatment decisions and tumor classification (NIH  The Cancer Genome Atlas).